Valuation: Immatics N.V.

Market Cap 1.29B 1.13B 1.04B 960M 1.82B 125B 1.85B 12.46B 4.89B 60.87B 4.86B 4.75B 210B P/E 2026 *
-4.6x
P/E 2027 * -5.02x
Enterprise Value 1.11B 969M 894M 822M 1.56B 107B 1.58B 10.67B 4.19B 52.12B 4.16B 4.07B 180B EV / Sales 2026 *
23.6x
EV / Sales 2027 * 21.9x
Free-Float
74.82%
Yield 2026 *
-
Yield 2027 * -
1 day+1.28%
1 week-5.11%
Current month-6.52%
1 month+0.42%
3 months-13.91%
6 months-4.54%
Current year-9.81%
1 week 9.1
Extreme 9.1
9.92
1 month 9
Extreme 9
10.89
Current year 8.55
Extreme 8.55
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Director

48,000 0.0358%
06-16Free

Director

48,000 0.0358%
06-16Free

Director

48,000 0.0358%
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%-5.11%+58.89%-15.82% 1.28B
-1.39%-6.15%+56.05%+124.73% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.27%-5.77%+6.75%+433.06% 23.87B
+1.76%-1.65%-16.86%-15.01% 22.86B
+3.51%+10.88%+44.84%-3.33% 20B
+1.94%+0.21%+39.31%-27.77% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+11.91%+50.03%+712.88% 15.19B
-0.39%-1.00%+26.08%+186.49% 14.02B
Average +2.73%-0.17%+54.25%+186.06% 24.05B
Weighted average by Cap. +2.10%+0.42%+52.44%+169.01%

Financials

2026 *2027 *
Net sales 47.04M 41.13M 37.94M 34.88M 66.08M 4.53B 67.21M 453M 178M 2.21B 177M 173M 7.63B 49.11M 42.94M 39.61M 36.41M 68.99M 4.73B 70.17M 473M 186M 2.31B 184M 180M 7.96B
Net income -278M -243M -225M -206M -391M -26.79B -398M -2.68B -1.05B -13.09B -1.05B -1.02B -45.13B -278M -243M -225M -206M -391M -26.8B -398M -2.68B -1.05B -13.1B -1.05B -1.02B -45.14B
Net Debt -186M -163M -150M -138M -262M -17.91B -266M -1.79B -703M -8.75B -699M -684M -30.18B -219M -192M -177M -163M -308M -21.11B -313M -2.11B -829M -10.32B -824M -806M -35.56B
Logo Immatics N.V.
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Employees
678
Date Price Change Volume
15/07/26 $9.470 +1.28% 477,292
14/07/26 $9.350 +1.30% 194,610
13/07/26 $9.230 -4.65% 178,908
10/07/26 $9.680 -2.81% 264,070
09/07/26 $9.960 -0.20% 280,585
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.470USD
Average target price
18.89USD
Spread / Average Target
+99.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock